Writing Committee on behalf of the COM99 Study Group* Background-Medication nonadherence is common and results in preventable disease complications. This study assessed the effectiveness of a multifactorial intervention to improve both medication adherence and blood pressure control and to reduce cardiovascular events. Methods and Results-In this multicenter, cluster-randomized trial, physicians from hospital-based hypertension clinics and primary care centers across Spain were randomized to receive and provide the intervention to their high-risk patients. Eligible patients were Ն50 years of age, had uncontrolled hypertension, and had an estimated 10-year cardiovascular risk greater than 30%. Physicians randomized to the intervention group counted patients' pills, designated a family member to support adherence behavior, and provided educational information to patients. The primary outcome was blood pressure control at 6 months. Secondary outcomes included both medication adherence and a composite end point of all-cause mortality and cardiovascular-related hospitalizations. Seventy-nine physicians and 877 patients participated in the trial. The mean duration of follow-up was 39 months. Intervention patients were less likely to have an uncontrolled systolic blood pressure (odds ratio 0.62, 95% confidence interval 0.50 to 0.78) and were more likely to be adherent (odds ratio 1.91, 95% confidence interval 1.19 to 3.05) than control group patients at 6 months. After 5 years, 16% of the patients in the intervention group and 19% in the control group met the composite end point (hazard ratio 0.97, 95% confidence interval 0.67 to 1.39). Conclusions-A multifactorial intervention to improve adherence to antihypertensive medication was effective in improving both adherence and blood pressure control, but it did not appear to improve long-term cardiovascular events.
Nevertheless, BP control rates are far below the Healthy People 2000 goal of 50%. [3] [4] [5] The situation in Spain is similar, with at best 40% of patients with hypertension under control. 3, 6 
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A major modifiable reason for the lack of BP control is medication nonadherence, where adherence is defined as the extent to which a person's behavior corresponds with the recommendations of their healthcare provider. 7 In general, poor adherence to medications is associated with the development of complications, disease progression, avoidable hospitalizations, premature disability, and death. [7] [8] [9] [10] The same is true for adherence to antihypertensive medications. 11, 12 Most previous adherence intervention studies share the following methodological limitations: A lack of patient-centered outcomes; limited statistical power; short duration of follow-up; unreliable measures of adherence; and limited generalizability due to their intensity and complexity. 13, 14 The objective of the present study was to assess the effectiveness of a simple, multifactorial intervention aimed at increasing antihypertensive medication adherence, improving BP control, and reducing cardiovascular events in high-risk patients with uncontrolled hypertension. The intervention was designed to be implemented in resource-poor settings, and it combined behavioral, cognitive, and social support components. The behavioral component included counting pills in front of the patients. Counting pills by doctors is a routine activity in most clinical trials, and patients tend to adhere better in clinical trials than in routine clinical practice. 15, 16 On the basis of prior research, we hypothesized that this Hawthorne effect could be used to improve medication adherence in routine practice. 15, 17 In the present study, adherence was monitored electronically, and study participants were followed up for up to 5 years. A cluster-randomized design that randomized physicians was chosen to avoid within-physician contamination.
Methods

Study Design
The study was approved by the ethics committees of the Hospital General de Vic (Barcelona, Spain) and Hospital de la Princesa (Madrid, Spain). In this multicenter cluster-randomized trial, participating physicians from hospital-based hypertension clinics and primary care centers across Spain were randomized in blocks of 2 within their site of practice. Block randomization was used to ensure that physicians were balanced across intervention and control groups within hospitals and primary care clinics. Randomization was centralized through a single coordinating center, and the sequence was concealed until interventions were assigned. A computer-generated random-number list was used to randomize physicians, and investigators were not aware of the randomization scheme. The trial was actively monitored by both internal and external quality control auditors.
Participants
Patients were Ն50 years of age; they had uncontrolled essential hypertension, as defined by an average systolic BP (SBP) Ն140 mm Hg and/or an average diastolic BP (DBP) Ն90 mm Hg; and they had a calculated 10-year cardiovascular risk Ͼ30%, as defined by the World Health Organization/International Society of Hypertension 1999 guidelines. 18 There were only 2 exclusion criteria: Participation in another clinical trial in the preceding 3 months and refusal/incapacity to provide informed consent. There were 2 coordinating centers (in Catalonia and Madrid, Spain), which separately recruited physicians. Patients were recruited by their physicians after assessment for eligibility. The coordinating center in Catalonia was also in charge of randomization, the validation of patients' eligibility criteria, the provision and analysis of the Medical Events Monitoring Systems (MEMS) containers (Aardex Ltd, Zug, Switzerland), the provision and calibration of semiautomatic sphygmomanometers, data entry, and study quality control. Patients were recruited between January 2000 and July 2002 and were followed up until December 2005.
We administered a survey to all study physicians to assess their characteristics across intervention and control groups. Sixty-nine (87%) of 79 physicians who actively recruited patients responded to the survey. Characteristics of recruiting physicians are depicted in Table 1 . There were no differences in the survey response rate between control and intervention groups.
Study Intervention
Patients in the control group received standard care, but they followed the same schedule of visits as the intervention group. Patients in both groups had 2 baseline visits 1 week apart and before study initiation to ensure that they met study criteria. These baseline visits were followed by a study initiation visit in the same month, during which patients in both groups received their MEMS devices; this visit constituted the beginning of the study. Follow-up visits occurred at 1, 3, and 6 months after study initiation and every 6 months thereafter. Medication changes were not allowed in either group until the 3-month follow-up visit unless there was intervening severe hypertension. The intervention to improve adherence in the treatment group lasted 6 months and consisted of 3 main components: (1) The counting of pills during physician visits, (2) designation of a family member to support adherence behavior, and (3) provision of an information sheet to patients at the start of the intervention. Patients were supposed to bring back the information sheet at each follow-up visit. If they did not, they were provided a new sheet at the start of the follow-up visit.
The information sheet included information on each BP medication dose and frequency, potential medication side effects, what to do if a dose was missed, what to do when the medication was running low, and how different types of antihypertensive medication could be taken together. It also included 2 questions for the patient to complete before each visit: One question on any problems taking the medication since the last visit and the other question on whether the patient experienced any side effects. Space was provided on the information sheet for patients to record BP readings, including self-measurements, and their current antihypertensive regimen. Patients were encouraged to measure their BP every other week, 19 and they were given calendars to mark the day that they took their medication. All intervention physicians underwent an initial 2-hour session on motivational interviewing techniques to promote patient adherence. 20 Physicians were advised to avoid confrontation and to respect patients' autonomy. Case vignettes representing confrontational and motivational interviewing scenarios were used during the training.
Outcome Measures
The primary outcome was SBP and DBP control at the end of the first 6 months of follow-up. Medication adherence over 6 months of follow-up was the secondary outcome. As an additional exploratory outcome, we included a composite end point of all-cause mortality and admission to a hospital for any cardiovascular event at 5 years of follow-up. The end points were defined identically to those in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. 21 The end points were adjudicated by a clinical events committee that was blinded to the patients' treatment group.
Three BP readings were obtained at each visit with a semiautomatic oscillometric BP monitor (Omron 705-CP, Omron Healthcare Group, Kyoto, Japan) that could print the readings. Each reading was printed and attached to the data collection instruments. The average of the 3 readings was used in the analysis.
Adherence was measured electronically with MEMS bottles (Aardex Ltd, Zug, Switzerland) during the first 6 months of follow-up. Patients were informed of the MEMS functionality. Because of cost limitations, only 1 MEMS bottle was provided per patient, and fixed-dose combination antihypertensive medications were encouraged when a patient required more than 1 BP medication. Therefore, when a patient was taking a fixed-dose combination antihypertensive medication, that was the one introduced in the MEMS bottle. If the patient was not using combination medications, the drug the patient had been taking for the longest period of time was the one monitored electronically. The average number of antihypertensive drugs used was 2.2 (SD 1.0), and the average number of drugs monitored electronically was 1.3 (SD 0.4). Accordingly, the average percentage of antihypertensive drugs monitored electronically per patient was 67% of those taken. For the medications monitored, we defined adherence as the percentage of days on which the correct number of doses was taken. Two additional adherence measures were assessed: Medicationtaking adherence and medication-timing adherence. Medication-taking adherence was defined as the percentage of prescribed doses taken, whereas medication-timing adherence was the percentage of prescribed doses taken on time. We allowed a 12-hour window for medication taken once daily and a 6-hour window for medications taken twice daily.
Statistical Analysis
Sample size estimates accounted for the cluster-randomized design. Because of low initial enrollment, sample size estimates had to be downwardly adjusted from a cluster size of 25 patients per physician to 11 patients per physician. With the assumption of an intraclass correlation coefficient of 0.05 and 12% of patients lost to follow-up, an enrolled sample size of 900 patients (ie, 450 per arm) equated to an effective sample size of 264 patients per arm. Therefore, with 264 patients per arm and a type I error of 0.05, we estimated 80% power to detect a 3.9-mm Hg change in SBP and a 2.7-mm Hg change in DBP.
Continuous baseline variables were compared with either a 2-sample t test or the Wilcoxon test. Categorical variables were compared with a 2 test.
Outcomes were analyzed on an intention-to-treat basis. Mean BP was analyzed with generalized estimating equation repeated-measures ANOVA. The generalized estimating equation clusters were defined by multiple patients sharing the same physician and the repeated measures (up to 3, ie, for the 1, 3, and 6-month visits) for each patient. Because the distribution of adherence measures appeared to be exponential, generalized estimating equation gamma and logistic regression models were used to analyze the continuous and binary measures of medication adherence, respectively. Nonadherence was defined as measured adherence Ͻ80%. This cutoff is widely used and has been shown to be associated with hypertensive clinical outcomes. 22 The composite cardiovascular outcome was analyzed as time to event with Kaplan-Meier estimation and Cox proportional hazards regression models. Physician clusters were accounted for with the COVSANDWICH (AGGRE-GATE) option in Proc PHREG in SAS version 9.1 (SAS Institute Inc, Cary, NC). 23 Statistical analyses were performed by an independent group blinded to group assignment. A 2-sided ␣-level of 0.05 was considered statistically significant.
Results
Between January 2000 and July 2002, 147 physicians were recruited and randomized to the control and intervention groups (Figure 1 ). Fifty-four physicians (24 in the control arm and 30 in the intervention arm) withdrew before recruiting any patients. Fourteen physicians (11 in the control arm and 3 in the intervention arm) withdrew study consent before their 40 patients began follow-up. Twelve patients (5 in the control arm and 7 in the intervention arm) were excluded because of protocol violations. Eight patients (3 in the control arm and 5 in the intervention arm) did not have follow-up data. Therefore, 79 physicians (39 in the control arm and 40 in the intervention arm) and 875 of their patients (457 in the control arm and 418 in the intervention arm) were available for complete analysis. Among those, MEMS data were not available for 78 patients (8.9%) for different reasons (14 devices were lost, 2 patients never used the MEMS, 4 MEMS were defective, and 58 MEMS were not returned by the patient or the investigator). There were no statistically significant differences in the distribution of those patients between the intervention and the control group. Tables 1 and 2 show the characteristics of physicians and patients, respectively, in the control and intervention groups. All characteristics were similar with the exception that baseline DBP, heart rate, and self-reported medication nonadherence were significantly higher among patients in the intervention group than among control group patients.
The mean duration of patient follow-up was 39 months, and 67% of the patients had at least 36 months of follow-up. The intraclass correlation coefficients for the outcomes of interest were as follows: 0.197 for SBP, 0.194 for DBP, 0.107 for adherence, and 0.063 for combined cardiovascular events. Table 3 shows the study results for BP and adherence outcomes in the first 6 months of follow-up. At 6 months, intervention patients had significantly lower mean SBP (148.9 versus 151.1 mm Hg, Pϭ0.008) and lower mean DBP (81.9 mm Hg versus 83.0 mm Hg, Pϭ0.013) than control patients. Moreover, intervention patients were less likely to have an uncontrolled SBP (ie, Ն140 mm Hg) than control patients (odds ratio 0.62, 95% confidence interval [CI] 0.50 to 0.78). On the other hand, intervention patients were not less likely to have an uncontrolled DBP (ie, Ն90 mm Hg) than control patients (odds ratio 0.94, 95% CI 0.73 to 1.20). Differences of Ϸ2 mm Hg in SBP between groups persisted over the 5 years of follow-up, whereas differences in DBP between groups were Ͻ1 mm Hg after 18 months of follow-up ( Figure 2) . Only a few of the SBP differences after the 6-month visit were statistically significant.
Patients in the intervention group also appeared to be more adherent over the 6 months of the intervention, because they took their correct dose on a greater proportion of days than patients in the control group (92.2% versus 89.0%, respectively; Pϭ0.002) and were more likely to be at least 80% adherent (odds ratio 1.91, 95% CI 1.19 to 3.05; Table 3 ). For the other adherence measures, intervention patients were also more likely to achieve an adherence value of Ն80% over the 6-month period. Expanded Tables I, II , and III and additional descriptions of the methods used in the present study are available in the online-only Data Supplement.
During the study, it was discovered that the MEMS chips of 45 containers malfunctioned at least once in the study, which resulted in inflated measurements of between 4 to 8 uses per day. The malfunctioning MEMS containers were replaced by the manufacturer, who also developed an algorithm to identify and delete invalid readings. Through this algorithm, we estimated that Ϸ5% of all readings on the defective devices were invalid. As a sensitivity analysis, we repeated the analysis excluding the 45 patients who had defective devices, and the results did not change (data not shown). After 5 years of follow-up, 153 patients had at least 1 of the composite cardiovascular events: 67 (16%) in the intervention group and 86 (19%) in the control group (Figure 3 ). Although intervention patients had fewer events than control patients, after adjustment for DBP, age, sex, self-reported measures of adherence, and cardiovascular risk profile, this difference was not statistically significant (hazard ratio 0.97, 95% CI 0.67 to 1.39).
Discussion
This multicomponent, low-intensity intervention to improve adherence to antihypertensive medication was effective in improving both BP control and adherence. Although the magnitude of the SBP effect appeared small (a difference of 2 mm Hg between groups), 1 large meta-analysis has suggested that such differences could be associated with a 10% reduction in stroke and a 7% reduction in coronary heart disease mortality. 1 The strengths of the study include the cluster-randomized design, which avoided study contamination that could have resulted from individual physicians treating patients in both study arms. We also assessed adherence objectively, used valid methods to measure BP, and had adequate power for both the BP and adherence study outcomes. Moreover, our findings are consistent with the findings of other recent studies. For example, a smaller study by Qureshi et al 25 tested a physician-targeted educational intervention. The intervention consisted of 1 day of training, during which the seventh report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure and the report of the Fourth Working Party of the British Hypertension Society, modified for the Indo-Asian population, were reviewed. The intervention was effective at improving patient adherence compared with the usual-care groups (48% versus 32%, respectively; PϽ0.05). Adherent patients experienced greater decreases in SBP than nonadherent patients (PϽ0.05), but the differences were not statistically significant for DBP. Another study by Ogedegbe et al 26 tested an intervention that consisted of motivational interviewing sessions every 3 months (ϫ4) that targeted medication adherence behavior among low-income black women with uncontrolled BP. In that study, baseline adherence was measured with MEMS during a 3-month run-in period, and patients were followed up afterward for an additional 9 months. The intervention was associated with a nearly 20% absolute increase in adherence levels at 12 months but not with statistically significant changes in BP. BP decreased in both groups, but the study did not report results on the association between adherence levels and BP control.
The fact that mean adherence was close to 90% in both groups in the present study could suggest a Hawthorne effect on both groups, whereby patients' knowledge that their adherence was being monitored caused them to change their behavior accordingly. Periods longer than 6 months might be required to observe a significant attenuation of the Hawthorne effect. [27] [28] [29] Although we hypothesized that counting pills could promote a Hawthorne effect in the intervention group, the MEMS bottles also may have resulted in a Hawthorne effect in both study arms, resulting in smaller than expected differences in adherence between groups. On the other hand, high antihypertensive medication adherence rates have also been found in studies measuring adherence with pharmacy refill methods, thus indicating that high levels of adherence might not always be attributable to the Hawthorne effect. 30 Regardless of whether there was a Hawthorne effect, we found clinically and statistically significant differences be-tween the intervention and control groups in the present study outcomes. We did not, however, observe a direct association between adherence and BP control (data not shown). Therefore, it is possible that the study intervention improved BP control through mechanisms other than improved adherence. For example, the intervention may have helped overcome clinical inertia (ie, clinicians' reluctance to intensify therapy), resulting in better overall BP control. 31 However, changes in BP medication were not allowed by protocol until the third month of follow-up, which suggests that BP improvements were not the result of overcoming clinical inertia. Although other factors may account for the BP improvement, we were likely underpowered to detect the association between adherence and BP control owing to the overall high levels of adherence in both groups, with limited variability. 15, 32, 33 In addition, Ϸ37% of the patients were using at least 1 antihypertensive medication for which adherence was not monitored electronically. Perhaps with the additional assessment of adherence for these medications, we would have seen a stronger association between adherence and BP control.
The present study has additional limitations. As mentioned previously, we had a problem with some of the MEMS containers that resulted in invalid readings; however, the inclusion or exclusion of data from the affected participants did not substantively influence our findings. Next, although we instructed physicians to keep a log of how many patients were offered enrollment in the study, many physicians did not complete these logs. Therefore, we are unable to comment on how the present study population differed from the larger, eligible patient population. A similar situation occurred with the physicians; an important proportion withdrew without recruiting patients and no information is available on them. Thus, we have a limitation with regard to evaluating the generalizability of the present study results to the larger population of both patients and physicians. On the other hand, patients included in the study met the eligibility criteria of high cardiovascular risk, and complete clinical information was available at baseline. Information on participating physicians was also available from the physician survey. Finally, adherence is not the only thing that explains poor rates of BP control. As mentioned above, clinician factors, such as clinical inertia, may also play an important role in unsatisfactory rates of BP control. 31 Therefore, future studies should assess and address both patient adherence and the need for clinician intensification of antihypertensive medication simultaneously. Future studies will also be needed to elucidate the impact of this type of intervention on cardiovascular morbidity and mortality, because this study was underpowered for those outcomes.
In summary, we conclude that a multifactorial intervention to improve adherence to antihypertensive medication was effective in improving both adherence and BP control. Although the effect size was small, we did observe high levels of adherence in both arms. This suggests that in addition to the intervention described, other factors such as the Hawthorne effect may have contributed to these results. The relative importance of various components of this intervention, including a potential Hawthorne effect, in improving adherence and BP control has yet to be determined.
